×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Videos
Maps
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
SELLAS Life Sciences Reports Full Year 2023 Financial Results and Provides Corporate Update
Yahoo Finance
Announced Phase 2a study of SLS009 in r/r AML Showing 50% Response Rate in the Selected Optimal Dose of 30 mg BIW Exceeding the Targeted 20%...
2 months ago
Sellas Life Sciences Group: A Lottery Ticket With An Estimated 6x Payout (NASDAQ:SLS)
Seeking Alpha
Summary · SELLAS Life Sciences Group, Inc. is a late-stage biotech company with a leading drug candidate, Galinpepimut-S, or GPS, that has a 44%...
1 month ago
SELLAS Announces Positive Phase 2 Preliminary Data of SLS009 in r/r AML Achieving a 100% Response Rate in ...
GlobeNewswire
The Company Filed IP Protection Related to the ASXL1 Mutation, a Highly Prevalent Gene Mutation in Myeloid Malignancies and Solid Tumors...
1 month ago
Sellas sends 2 execs packing while awaiting phase 3 cancer vax readout
Fierce Biotech
Sellas Life Sciences Group is sending two executives out the door as part of efforts to optimize resources around advancing its clinical...
2 months ago
Sellas Life Sciences Shares Drop 31% After Direct Offering Prices
MarketWatch
By Chris Wack Sellas Life Sciences Group shares were down 31% at $1.07 after the company entered into definitive agreements with two...
2 months ago
SLS Stock Earnings: SELLAS Life Sciences Gr Misses EPS for Q1 2024
InvestorPlace
SLS stock results show that SELLAS Life Sciences Gr missed analyst estimates for earnings per share the first quarter of 2024.
3 weeks ago
Can SELLAS Life Sciences Group (NASDAQ:SLS) Afford To Invest In Growth?
Yahoo Finance
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the right price.
1 week ago
Sellas announces positive results from Phase I Mesothelioma trial
Clinical Trials Arena
The company has said that its cancer treatment in combination with Opdivo is able to increase overall survival by more than 200%.
5 months ago
SELLAS Life Sciences Reports First Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire
Announced Independent Data Monitoring Committee's (IDMC) Recommendation to Continue the Phase 3 REGAL Study in Patients with Acute Myeloid...
3 weeks ago
SELLAS Life Sciences to Host Corporate Update Call on March 26, 2024, at 8:15 am ET
GlobeNewswire
(NASDAQ: SLS) (“SELLAS'' or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a...
2 months ago